Clinical Trial Update: Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab with or without carboplatin and paclitaxel in recurrent or stage IIIB-IV non-small cell lung cancer has completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-01-05